https://www.selleckchem.com/products/triparanol-mer-29.html Formulation F6 was selected as the optimum formulation due to the fastest in-vitro (135.33±11.52 s) and in-situ disintegration time (88.67±13.56s) among all the formulations (p less then 0.05). Increase in starch component decreases disintegration time of ODT. The powder flow fell under the category of fair flow. Generally, it was observed that freeze drying method produced smaller particle size granules compared to wet granulation method. ODT produced from freeze drying method had shorter disintegration time compared to ODT from wet granulation batch. In conclusion, a novel co-processed excipient comprised of xylitol, starch and crospovidone XL-10, produced using freeze drying method with fast disintegration time, good compressibility and palatability was developed and characterized. The co-processed excipient is suitable for ODT application.To evaluate the anticancerous effects of different dilutions of metformin were evaluated for in vitro anti-cancerous effects, primarily breast cancer cells (MCF-7, MDA-MB-231). This prospective experimental study was conducted in Department of Pharmacology & Therapeutics BMSI in alliance with PCMD. The duration of study was from March 2016 to February 2017. For evaluating the anticancerous effects of different dilutions of Metformin (0.5μM -100μM) we used 4 different cancerous cells lines; MCF-7, HT-29, MDA-MB-231 and Hela. For assessment of anticancerous effects we used MTT assay by which assessed IC50, SI, % viability of all cells and Trypan blue exclusion assay for only MCF-7 cell line. The % viability of MCF-7 was significantly decreases (χ2 (2) = 26.48, p= less then 0.001) in dose dependent manner from 99.8±0.2 to 39.71±1.3. For MDA-MB-231% viability significantly reduced (χ2 (2) =26.48, p= less then 0.001) from 99.474± 0.298 to 51.55±4. However Metformin had statistically no significant dose dependent effects on % viability of MCF-10 (χ2 (2) = 11.709, p=0.069). M